SCHEMBL7215504

SCHEMBL7215504

COc1ccc2nc3[nH]cnc(Nc4cccc(Br)c4)c-3c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 13/20 0.60
FBP1 P09467 3/20 0.48
ABCG2 Q9UNQ0 3/20 0.46
ERBB2 P04626 2/20 0.45
TNF P01375 1/20 0.45
KDM4E B2RXH2 1/20 0.45
GAK O14976 1/20 0.45
MAPK13 O15264 1/20 0.45
ABL1 P00519 1/20 0.45
CYP1A2 P05177 1/20 0.45
CDK1 P06493 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
MAPT P10636 1/20 0.45
CYP2C9 P11712 1/20 0.45
SRC P12931 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
EPHB2 P29323 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7222295 0.83 EGFR (0.54) EGFRFBP1ABCG2EPHB2MKNK1
Hydrochloric Acid SCHEMBL7218002 0.82 EGFR (0.53) EGFRFBP1ABCG2EPHB2MKNK1
SCHEMBL3663489 0.75 EGFR (1.00) EGFRFBP1ABCG2ERBB2KDM4E
SCHEMBL7218006 0.72 MMP12 (0.48) KDM4ECYP1A2CDK1CYP3A4CYP2D6
SCHEMBL7216427 0.70 NPY5R (0.47) EGFRABCG2ERBB2KDM4EABL1
SCHEMBL7497657 0.70 EGFR (0.54) EGFRABCG2KDM4EABL1CYP1A2
SCHEMBL14726414 0.69 ABCG2 (0.74) EGFRABCG2KDM4EMAPT
Hydrochloric Acid SCHEMBL7499724 0.69 EGFR (0.55) EGFRABCG2KDM4EABL1CYP1A2
SCHEMBL7215498 0.69 EGFR (1.00) EGFRFBP1ABCG2ERBB2KDM4E
SCHEMBL19633634 0.69 EGFR (0.72) EGFRERBB2GAKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6596726-B1 Method of inhibiting epidermal growth factor by treating, with an effective inhibiting amount, a mammal, in need thereof inhibit the epidermal growth factor receptor and related receptors and, in particular, their tyrosine kinase enzyme WARNER LAMBERT COMPANY 2003-07-22 US disclosed
US-5679683-A USEFUL FOR TREATING CANCER, ARTHRITIS, PSORIASIS, VASCULAR RESTENOSIS AND ANGIOGENESIS WARNER-LAMBERT COMPANY (US) 1997-10-21 US disclosed
EP-0741711-A1 TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY WARNER-LAMBERT COMPANY (US) 1996-11-13 EP disclosed
WO-1995019970-A1 TRICYCLIC COMPOUNDS CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR RECEPTOR FAMILY WARNER-LAMBERT COMPANY (US) 1995-07-27 WO disclosed